CION Ameerpet
CAR-T cell therapy for blood cancer is an advanced option for select patients whose disease has come back or not responded to standard treatment. At CION, our tumour board honestly evaluates whether you may be eligible, and we coordinate access to CAR-T at qualified centres. You deserve clear answers, not hype, and we walk this journey with you.
A clear, plain-language explanation for patients hearing this term for the first time.
CAR-T cell therapy is a type of immunotherapy. CAR stands for chimeric antigen receptor. The idea is simple to picture, even though the science is advanced.
Your T-cells are part of your immune system. In blood cancer, they often fail to recognise cancer cells. In CAR-T therapy, doctors collect your T-cells, send them to a special lab, and re-engineer them to spot a marker on cancer cells. These trained cells are grown in large numbers and then returned to your body.
Once inside you, the modified cells search for and attack the cancer. Because the cells come from you, this is called an autologous therapy.
CAR-T is not a first-line treatment. It is usually considered when blood cancer has relapsed (come back) or is refractory (did not respond to standard treatment). It is a serious, complex therapy that needs careful patient selection and an experienced, specialised centre.
In CAR-T therapy, your own T-cells are removed, re-engineered in a specialised lab to recognise a marker on cancer cells, then multiplied and infused back into you. Because the cells come from your own body, it is called an autologous therapy — not a donor transplant.
Knowing the journey ahead helps reduce fear. Here is what the process generally looks like.
Your reports are reviewed to confirm the cancer type, stage, and whether CAR-T is appropriate for you.
Blood is drawn through a machine that separates out your T-cells and returns the rest to you.
In a specialised lab, the T-cells are modified to recognise your cancer, then multiplied over a few weeks.
While cells are being made, you may receive treatment to keep the disease controlled.
A short course of low-dose chemo prepares your body to receive the new cells.
The CAR-T cells are infused back into you, much like a blood transfusion.
You are watched carefully for several weeks for side effects, which can be serious and need expert management.
CAR-T is approved or studied for specific blood cancers, mostly after other treatments have been tried.
In certain children and young adults whose leukaemia relapsed or did not respond.
Including diffuse large B-cell lymphoma (DLBCL) that returned after chemotherapy.
In selected relapsed or refractory cases.
For some patients after multiple prior treatments.
In specific relapsed or refractory situations after several earlier therapies.
This is not a full list, and approvals change over time. Whether CAR-T fits your exact diagnosis is a decision only a specialist can make after reviewing your case.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Every CION patient is discussed by a tumour board. If CAR-T is not right for you, we will say so, and guide you to the blood cancer treatment in Hyderabad that genuinely helps.
Honest eligibility matters more than excitement about a new therapy. These are factors a specialist weighs.
If you do not meet these, it does not mean you are out of options. Other effective treatments, including newer drugs and clinical trials, may suit you better. We will explain each one honestly.
An honest picture of access, cost, and timelines, so you can plan with clear eyes.
CAR-T cell therapy is an emerging option in India. It is available at a limited number of specialised centres, and access is growing as more facilities develop the needed expertise.
A few realities are worth knowing early. The therapy is expensive compared with standard treatment, and costs vary by centre and product. The process takes several weeks, from cell collection to infusion and recovery. It also requires intensive monitoring for serious side effects, which is why centre experience matters so much.
CAR-T is not a guaranteed cure, and outcomes differ from person to person. For the right patient, however, it can offer a meaningful chance when other treatments have stopped working.
At CION, we do not perform CAR-T to chase a trend. We assess whether it genuinely fits your situation, coordinate access at a qualified centre when it does, and stay involved in your overall care.
Our role is honest evaluation, clear guidance, and steady support, never overpromising.
Every patient's case is discussed by a team of specialists, so the recommendation is balanced, not one doctor's opinion.
An unhurried, doctor-led discussion of your diagnosis, prior treatments, and realistic options.
If CAR-T is not right for you, we say so plainly and guide you to better-suited treatment.
When CAR-T fits, we help coordinate access at a qualified, experienced centre.
We order only what truly helps your decision, with transparent costs upfront.
With 17 super-specialist oncologists and 35+ centres across Telangana and AP, you are never navigating this alone.
CAR-T is not a guaranteed cure, and outcomes differ from person to person. For carefully selected patients whose disease has relapsed or not responded, it can offer a meaningful chance when other treatments have stopped working — which is exactly why patient selection and centre experience matter so much.
Patients and caregivers share what it felt like to be heard, understood, and guided through difficult blood cancer decisions at CION.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.CAR-T cell therapy is a form of immunotherapy. Your own immune T-cells are collected from your blood and sent to a special lab. There, they are re-engineered to recognise a marker on your cancer cells, then grown in large numbers. These trained cells are infused back into you, where they seek out and attack the blood cancer. Because the cells come from your own body, it is called an autologous therapy. It is an advanced, complex treatment used mainly when blood cancer has relapsed or has not responded to standard treatment. It is not a first-line option, and not everyone is a candidate.
Yes, CAR-T cell therapy is available in India, though it is still an emerging treatment offered at a limited number of specialised centres. Access is gradually expanding as more facilities build the necessary expertise and infrastructure. The therapy requires advanced lab capability, careful patient selection, and intensive monitoring for side effects. At CION, we evaluate whether CAR-T genuinely fits your situation. When it does, we help coordinate access at a qualified, experienced centre, and we stay involved in your overall care. If it is not the right choice for you, we will explain that honestly and guide you toward treatment that truly helps.
CAR-T therapy is approved or studied for specific blood cancers, mostly after other treatments have been tried. These include B-cell acute lymphoblastic leukaemia (ALL) in certain children and young adults, large B-cell lymphoma such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, some follicular lymphoma cases, and certain relapsed or refractory multiple myeloma. Approvals and indications change over time as research advances. Whether CAR-T fits your exact diagnosis depends on the cancer type, the cell marker involved, your prior treatments, and your overall health. Only a specialist can decide this after reviewing your full case. Our tumour board reviews each patient before making any recommendation.
Eligibility depends on several factors. Usually the blood cancer must be a type CAR-T is designed to treat, and it must have relapsed or be refractory after standard treatments. Your heart, lungs, liver, and kidneys must function well enough to tolerate the therapy. Active serious infections must be controlled first. Doctors also assess your overall fitness and ability to handle side effects like cytokine release syndrome and neurological effects. Not everyone qualifies, and that is an honest reality. If you are not eligible, it does not mean you are out of options. Other effective treatments, including newer drugs and clinical trials, may suit you better, and we will explain each one clearly.
No. CAR-T cell therapy is not a guaranteed cure, and we will never promise one. For carefully selected patients whose blood cancer has relapsed or not responded to other treatments, it can offer a meaningful chance of long-term control when other options have stopped working. However, outcomes vary from person to person. Some patients respond very well, others less so, and the cancer can sometimes return. The therapy also carries serious risks that need expert management. Our role is to give you an honest picture, weigh CAR-T against other treatments, and recommend what genuinely offers you the best chance, not what sounds most impressive.
CAR-T therapy can cause serious side effects that need expert monitoring. The two most important are cytokine release syndrome (CRS), which can cause fever, low blood pressure, and difficulty breathing, and neurological effects, which can cause confusion, trouble speaking, or seizures. Most side effects appear in the first few weeks after infusion and are managed by an experienced team. Other effects can include low blood counts, increased infection risk, and fatigue. This is exactly why CAR-T must be done at a specialised centre with staff trained to recognise and treat these reactions quickly. During your evaluation, we explain these risks honestly so you and your family can make an informed decision.
The full CAR-T process usually takes several weeks. After evaluation confirms you are a candidate, your T-cells are collected through a procedure called leukapheresis. The cells are then sent to a specialised lab to be re-engineered and multiplied, which typically takes a few weeks. During this time, you may receive bridging therapy to keep the cancer controlled. Before the cells are returned, you have a short course of conditioning chemotherapy. The cells are then infused back, followed by several weeks of close monitoring for side effects. Timelines vary by patient and centre. We help you understand each stage in advance so the journey feels less uncertain and you can plan with your family.
CAR-T cell therapy is expensive compared with standard blood cancer treatments, and the cost varies depending on the centre, the specific product used, hospital stay, and supportive care needed for side effects. Because it is an emerging therapy with complex lab work and intensive monitoring, the overall cost can be substantial. We believe you deserve honesty about money, not surprises. During your free consultation, we discuss realistic cost expectations transparently and help you plan. We also make sure CAR-T is genuinely the right choice before recommending it, because we make decisions for your healing, not for billing. If a more affordable treatment serves you equally well, we will tell you.
At CION, every case is first reviewed by a tumour board, so the recommendation reflects a team of specialists rather than a single opinion. You receive a free, doctor-led 45-minute consultation where we discuss your diagnosis, prior treatments, and realistic options without rushing. We honestly assess whether CAR-T is appropriate for you. When it is, we help coordinate access at a qualified, experienced centre and stay involved in your overall care. When it is not, we guide you to better-suited treatment. We order only the tests that truly help your decision, keep costs transparent, and walk this journey with you. With 17 super-specialist oncologists, you are supported by a whole team.
Not being eligible for CAR-T does not mean you are out of options, and we want to reassure you of that. Blood cancer treatment has advanced significantly, and several effective alternatives may suit your situation better. These can include targeted therapies, newer immunotherapy drugs, stem cell (bone marrow) transplant coordinated via partners in some cases, refined chemotherapy approaches, and clinical trials of promising treatments. The right choice depends on your specific cancer type, prior treatments, and overall health. Our tumour board reviews all of this together. During your free consultation, we explain each realistic option in plain language, with honest expectations about benefits and risks. You deserve a clear plan, and we walk this journey with you whatever the next step turns out to be.